

Caris Pharmatech Studies

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Mirati Therapeutics	849-001	KRAS G12C	Solid tumors	1/2	Adagrasib (MRTX849)	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Mirati Therapeutics	849-007	KRAS G12C	NSCLC	3	Adagrasib	A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Roche	BO41932	NTRK, ROS1, ALK, KRAS G12C, ATM, SETD2	Solid tumors	2	Cohort Dependent	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Fore Biotherapeutics	F8394-201: Subprotocol A	BRAF fusions	Solid tumors	2	FORE8394	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Turning Point Therapeutics, Inc	TPX-0005-07	NTRK FUSIONS	Solid tumors	2	TPX-0005/Repotrectinib	A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
AADI Bioscience	TSC-007	TSC1, TSC2	Solid tumors	2	ABI-009 nab-sirolimus	A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

CONFIDENTIAL

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Fore Biotherapeutics	F8394-201: Subprotocol B	BRAF V600E	CNS tumors	2	FORE8394	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
ArriVent BioPharma	FURMO-004	EGFR Exon 20 insertion mutation	NSCLC	3	Furmonertinib	A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Zentalis Pharmaceuticals	ZN-c3-005	n/a	Ovarian, fallopian tube, and primary peritoneal	2	ZN-c3	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
PCCTC	PRODIGY	HRR mutations (BARD1, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L)	Prostate (mCRPC)		n/a	IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations
Merus N.V.	MCLA-128-CL01	NRG1 fusions	Solid tumors	2	MCLA-128	***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

CONFIDENTIAL

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Boehringer Ingelheim	1403-0011	MDM2 amplification	Select solid tumors	2	BI 907828	***REFERRAL ONLY*** Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors
Boehringer Ingelheim	1479-0001	HER2	NSCLC	1	BI 1810631	***REFERRAL ONLY*** An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim	1403-0001	MDM2 amplification	Select solid tumors	1	BI 907828	***REFERRAL ONLY*** A Phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors
Boehringer Ingelheim	1403-0002	MDM2 amplification (not req. for sarcoma)	Select solid tumors	1	BI 907828, ezabenlimab	***REFERRAL ONLY*** A phase Ia/Ib, open-label, dose escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors.

CONFIDENTIAL